Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor

Journal of Neuroscience Research

Volumn 56, Issue 1, 1999, Pages 72-75

  Li, Xin Min ^a,b   Chlan Fourney, Jennifer ^a   Juorio, Augusto V ^a   Bennett, Vern L ^a   Shrikhande, Satish ^a   Keegan, David L ^a   Qi, Jin ^a   Boulton, Alan A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Olanzapine; p75; PC12 cells; Superoxide dismutase

Indexed keywords

NERVE GROWTH FACTOR RECEPTOR; OLANZAPINE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STRAIN; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROANATOMY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; KINETICS; PC12 CELLS; PIRENZEPINE; RATS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTORS, NERVE GROWTH FACTOR; RNA, MESSENGER; SUPEROXIDE DISMUTASE; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 0033118431     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19990401)56:1<72::AID-JNR9>3.0.CO;2-0     Document Type: Article

References (37)

1. Barret GL, Georgiou A. 1996. The low affinity growth factor receptor p75NGFR mediates death of PC12 cells after nerve growth factor withdrawal. J Neurosci Res 45:117-128.
2. Beasley CM, Tollefson GD, Tran PV. 1997. Efficacy of Olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58(Suppl 10):7-12.
3. Coyle JT. 1996. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 3:241-253.
4. DeLisi LE, Sakuma M, Rew, W. Kushner M, Hoff AL, Grimson R. 1997. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res (Neuroimaging Section) 74:129-140.
5. Ebendal T. 1992. Function and evolution in the NGF family and its receptors. J Neurosci Res 32:461-470.
6. Fainberg AP, Vogelstein B. 1983. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13.
7. Falloon IRH. 1992. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 55:4-15.
8. Frade JM, Rodriguez-Tebar A, Barde YA. 1996. Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature 383:166-168.
9. Furukawa K, Estus S, Fu W, Mark RJ, Mattson MP. 1997. Neuroprotective action of cycloheximide involves induction of bcl-2 and antioxidant pathways. J Cell Biol 136:1137-1149.
10. Greene LA, Kaplan DR. 1995. Early events in neurotrophin signalling via TRK and p75 receptors. Curr Opin Neurobiol 5:579-587.
11. Greene LA, Tischler A. 1982. PC12 pheochromocytoma cultures in neurobiological research. Adv Cell Neurobiol 3:373-414.
12. Jacobsen LK, Gied JN, Castellanos FX, Vaituzis AC, Hamburger SD, Kumra S, Lenane M, Rapoport JL. 1998. Progressive reduction of temporal lobe structures in childhood-onset schizophrenia. Am J Psychiatry 155:678-685.
13. Jeste DV, Lohr JB. 1989. Hippocampal pathologic findings in schizophrenia. A morphometric study. Arch Gen Psychiatry 46:1019-1024.
14. Kaplan DR, Miller FD. 1997. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 9:213-221.
15. Kong J, Xu Z. 1998. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18:3241-3250.
16. Levi-Montalcini R. 1987. The nerve growth factor 35 years later. Science 237:1154-1162.
17. Li XM, Juorio AV, Qi J, Boulton AA. 1998a. L-deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells. J Neurosci Res 53:235-238.
18. Li XM, Chlan-Fourney J, Qi J, Juorio AV, Bennett VL, Boulton AA. 1998b. Neuroleptics regulate neuroprotective genes. New Research. American Psychiatric Association Annual Meeting, May 30-June 4, 1998. Toronto, ON, Canada, p 91-92.
19. Littrell, KH, Johnson CG, Littrell S, Peabody CD. 1998. Marked reduction of TD with olanzapine. Arch Gen Psychiat 55:279-280.
20. LNTR: l'énigmatique récepteur des neurotrophines. Médecine/Sciences 13:978-986.
21. Nair TR, Christensen JD, Kingsbury SJ, Kumar NG, Terry WM, Garver DL. 1997. Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Res 74:141-150.
22. O'Brien J Barber R. 1998. Marked improvement in TD following treatment with olanzapine in an elderly subject. Br J Psychiatry 172:186-189.
23. Rabizadeh S, Bredesen DE. 1994. Is p75 involved in developmental neural cell death? Dev Neurosci 207-211.
24. Rabizadeh S, Oh J, Zhong L, Yang J, Biller CM, Butcher LL, Bredesen DE. 1993. Induction of apoptosis by the low-affinity NGF receptor. Science 261:345-348.
25. Selemon LD, Rajkowska G, Goldman-Rakic PS. 1995. Abnormally high neuronal density in the schizophrenic cortex. Arch Gen Psychiatry 52:805-181.
26. Stefanis L, Burke RE, Greene LA. 1997. Apoptosis in neurodegenerative disorders. Curr Opin Neurol 19:299-305.
27. Thoenen H, Barde YA. 1980. Physiology of the nerve growth factor. Physiol Rev 60:1284-1335.
28. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. 1997. Double blind comparison of olanzapine vs risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418.
29. Turner SW, Toone BK, Brett-Jones JR. 1986. Computerized tomographic scan changes in early schizophrenia: preliminary findings. Psychol Med 16:219-225.
30. Vazquez ME, Ebedal T. 1991. Messenger RNAs for trk and the low affinity NGF receptor in rat basal forebrain. NeuroReport 2:593-596.
31. Waddington JL, O'Callaghan E, Buckley P, Larkin C, Redmond O, Slack J, Ennis J. 1991. The age differences of MRI abnormalities in schizophrenia suggest early ventricular enlargement but later prominence of cortical atrophy. Schiz Res 5:188-189.
32. Wengenack TM, Curran GL, Poduslo JF. 1997. Postischemic, systematic administration of polyamine-modified superoxide dismulase reduces hippocampal CA1 neurodegeneration in rat global ischemia. Brain Res 754:46-54.
33. Woods BT, Yurgelun-Todd D. 1991. Brain volume loss in schizophrenia: when does it occur and is it progressive? Schiz Res 5:202-204.
34. Woods BT, Yurgelun-Todd D, Benes FM, Frankenburg FR, Pope HG, McSparren J. 1990. Progressive ventricular enlargement in schizophrenia: comparison to bipolar disorder and correlation with clinical course. Biol Psychiatry 27:341-352.
35. Woolf NJ, Jacobs RW, Butcher LL. 1989. The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neurosci Lett 96:277-282.
36. Wyatt RJ. 1991. Early intervention with neuroleptics may decrease the long term morbidity of schizophrenia. Schiz Res 5:201-202.
37. Wyatt RJ, Henter ID. 1998. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res 32:169-177.